dc.contributor.author | Agostinetto, E | |
dc.contributor.author | Ameye, L | |
dc.contributor.author | Martel, S | |
dc.contributor.author | Aftimos, P | |
dc.contributor.author | Pondé, N | |
dc.contributor.author | Maurer, C | |
dc.contributor.author | El-Abed, S | |
dc.contributor.author | Wang, Y | |
dc.contributor.author | Vicente, M | |
dc.contributor.author | Chumsri, S | |
dc.contributor.author | Bliss, J | |
dc.contributor.author | Kroep, J | |
dc.contributor.author | Colleoni, M | |
dc.contributor.author | Petrelli, F | |
dc.contributor.author | Del Mastro, L | |
dc.contributor.author | Moreno-Aspitia, A | |
dc.contributor.author | Piccart, M | |
dc.contributor.author | Paesmans, M | |
dc.contributor.author | de Azambuja, E | |
dc.contributor.author | Lambertini, M | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-10-05T13:15:31Z | |
dc.date.available | 2022-10-05T13:15:31Z | |
dc.date.issued | 2022-07-20 | |
dc.identifier | 87 | |
dc.identifier | 10.1038/s41523-022-00452-8 | |
dc.identifier.citation | npj Breast Cancer, 2022, 8 (1), pp. 87 - | en_US |
dc.identifier.issn | 2374-4677 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5520 | |
dc.identifier.eissn | 2374-4677 | |
dc.identifier.eissn | 2374-4677 | |
dc.identifier.doi | 10.1038/s41523-022-00452-8 | |
dc.description.abstract | The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic performance using data extracted from ALTTO, a phase III trial evaluating adjuvant lapatinib ± trastuzumab vs. trastuzumab alone in patients with HER2-positive EBC. Our analysis included 2794 patients. After a median follow-up of 6.0 years (IQR, 5.8-6.7), 182 deaths were observed. Overall, PREDICT underestimated 5-year OS by 6.7% (95% CI, 5.8-7.6): observed 5-year OS was 94.7% vs. predicted 88.0%. The underestimation was consistent across all subgroups, including those according to the type of anti HER2-therapy. The highest absolute differences were observed for patients with hormone receptor negative-disease, nodal involvement, and large tumor size (13.0%, 15.8%, and 15.3%, respectively). AUC under the ROC curve was 73.7% (95% CI 69.7-77.8) in the overall population, ranging between 61.7% and 77.7% across the analyzed subgroups. In conclusion, our analysis showed that PREDICT highly underestimated OS in HER2-positive EBC. Hence, it should be used with caution to give prognostic estimation to HER2-positive EBC patients treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies. | |
dc.format | Electronic | |
dc.format.extent | 87 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | NATURE PORTFOLIO | en_US |
dc.relation.ispartof | npj Breast Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | RANDOMIZED CONTROLLED-TRIALS | |
dc.subject | PLUS ADJUVANT CHEMOTHERAPY | |
dc.subject | 70-GENE SIGNATURE | |
dc.subject | PROGNOSTIC MODEL | |
dc.subject | FOLLOW-UP | |
dc.subject | TRASTUZUMAB | |
dc.subject | VALIDATION | |
dc.subject | LAPATINIB | |
dc.title | PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-07-01 | |
dc.date.updated | 2022-10-05T13:14:59Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1038/s41523-022-00452-8 | en_US |
rioxxterms.licenseref.startdate | 2022-07-20 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35859079 | |
pubs.issue | 1 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1038/s41523-022-00452-8 | |
pubs.volume | 8 | |
icr.researchteam | Clin Trials & Stats Unit | en_US |
dc.contributor.icrauthor | Bliss, Judith | |
icr.provenance | Deposited by Mr Arek Surman on 2022-10-05. Deposit type is initial. No. of files: 1. Files: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.pdf | |